Notably, tafamidis, a pharmacological transthyretin-stabilizer, improved outcome of patients affected by transthyretin-related cardiac amyloidosis, a progressively more recognized clinical phenotype of HFpEF [156]. The gene discussed is TTR; the disease is cardiac amyloidosis.